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Variable (N)
Median time to
progression (p-value)
Median
overall survival
(p-value)
Treatment related
mortality at 2 years (p-value)
HCT year <2000 (47) 1.6 years (0.41) 4.9 months (0.04) 55% (0.001)
HCT year $ 2000 (102) 10 months 1.4 years 28%
Male (87) 10 months (0.34) 1.1 years (0.8)
Female (62) 1.2 years 8.8 months
Age > 50 years (65) 10 months (0.93) 1.6 years (0.14) 25% (0.08)
Age # 50 years (84) 1.1 years 7.6 months 47%
Durie Salmon Stage I/II (78) 1.1 years (0.81) 1.9 years (0.08)
Durie Salmon Stage III (71) 10 months 8.5 months
Myeloablative conditioning (52) 10 months (0.45) 5.3 months (0.08) 52% (0.009)
Reduced intensity conditioning (97) 10 months 1.3 years 29%
Related donor (114) 10 months (0.35) 1.4 years (0.27)
Unrelated donor (35) 10 months 8.5 months
Stem cell source peripheral blood (100) 1.2 years (0.11) 1.7 years (<0.001) 29% (0.002)
Stem cell source cord blood (3) 5.6 months 13 days
Stem cell source bone marrow (46) 7.5 months 5 months 54%
Disease status at HCT PR or better (76) 1.4 years (0.03) 1.7 years (0.001) 30% (0.016)
Disease status at transplant less than PR (72) 9 months 5.3 months 45%
Maintenance therapy given (12) 10 months (0.7) 2.9 years (0.06)
No maintenance therapy (137) 1 year 8.4 months
Relapsed/refractory disease (121) 9 months (<0.001) 7.8 months (<0.0001)
Primary responsive disease (26) Not reached 6.48 years
S178 Oral Presentations68
AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN MULTIPLE
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Introduction:High dose chemotherapy followed by autologous he-
matopoietic cell transplantation (auto HCT) for multiple myeloma
(MM) has shown improved survival compared to conventional che-
motherapy. However, the larger clinical trials evaluating the role
of auto HCT inMM have included patients who are generally youn-
ger than 65 years. Here we report the results of MM patients, age$
70 years, who received auto HCT at our institution.
Methods:We retrospectively analyzed 84 patients, who underwent
auto HCT between January 1999 and June 2010 at MDACC. Con-
ditioning regimen was Melphalan 140 mg/m2 (MEL 140) (N 5 9),
180 mg/m2 (MEL 180) (N 5 20), and 200 mg/m2 (MEL 200) (N
5 55). Disease response was assessed at day 100 post transplant.
Results: Pertinent patient and disease characteristics are summa-
rized in the Table.
Progression-Variable (N)Progression-free
survival
at 2 yearsfree
survival
at 5 years aOverall
survival
t 2 years
sOverall
urvival at
5 years
Non-relapse
mortality
(day100)All patients (84) 56% 28% 80% 66% 2%MEL-140 (9) 75% NA 75% NA 0MEL-180 (20) 62% 44% 94% 60% 0MEL-200 (55) 50% 21% 75% 72% 4%Relapse/Refractory
disease (24)41% NA* 64% 41%** 0Primary responsive
disease (60)63% 43% 89% 82% 3%Age $ 75 years (18) 73% 40% 83 83 6Age < 75 years (66) 52% 26% 79% 63% 2%*p value 5 0.008
**p value 5 0.005
Median age at transplant was 72 (70-80) years. Median number of
prior treatments was 1 (range: 1-8). Median time from diagnosis to
transplant was 8.5 (2.4-151) months. No patient was in CR prior
to auto HCT. Median CD341 cell count and TNC was 4.56
(0.72-11.1)  106/kg and 10.53 (2.25-57) x108/kg, respectively.
Median follow up is 2 (0.1-7.3) years. Grade III-IV organ toxicity
was seen in 35 (51%) patients. Grade III-IV toxicity in patientswho received MEL 140, MEL 180, and MEL 200 was 25%, 45%,
and 44%, respectively (p value . 0.05). Non-relapse mortality
(NRM) at 100 days was 2%. Two patients died in first 100 days. Dis-
ease response in evaluable patients (N5 79) at day 100 was: CR5 15
(19%); VGPR5 7 (9%); PR5 41 (52%); and SD 5 10 (13%). Me-
dian progression free survival (PFS) and overall survival (OS) from
auto HCT was 2.1 years (95% CI 1.78-3.69) and 5.6 years (95%
CI 5.51-NA), respectively. 2-year PFS and OS were 56% (95% CI
0.44-0.71) and 80% (95% CI 0.7-0.91), respectively. There was no
difference in NRM, PFS, or OS in different MEL groups. Similarly
there was no difference in TRM, PFS, and OS in patients$ 75 years
compared to the patients\ 75 years.
Conclusions: Auto HCT in myeloma patients age$ 70 years is safe
and feasible. Toxicity, NRM, response and survival were comparable
to younger myeloma patients. The age alone should not be a contra-
indication for auto HCT.69
INHIBITING IMMUNE SUPPRESSIVE PATHWAYS TO IMPROVE IMMUNO-
THERAPY FOR MYELOMA
Hallett, W.H.D., Drobyski, W.R., Johnson, B.D. Medical College of
Wisconsin, Milwaukee, WI
Myeloma is an incurable hematologic malignancy. Patients who
fail conventional treatments may be treated with high-dose therapy
followed by hematopoietic stem cell transplantation (HSCT). Un-
fortunately, these patients frequently relapse from sites of treat-
ment-resistant disease. Upon examining marrow and blood
samples frommyeloma patients, our laboratory confirmed recent ob-
servations by others showing high expression of B7-H1 on plasma
cells and high levels of the inhibitory receptor PD-1 (receptor for
B7-H1) on T cells in these patients.When tissues frommice bearing
myeloma (5T33 myeloma) were examined, we observed a similar
pattern of B7-H1 and PD-1 expression. Increased expression of
PD-1 on T cells (both CD4 and CD8) and NK cells in myeloma-
bearing mice correlated with tumor burden and was restricted to
areas of local tumor cell accumulation. CD81PD-11 T cells were
CD44hi/CD62L-, a large percentage bound annexin-V, and they
produced interferon-gamma, suggesting that these cells are termi-
nally differentiated effectors.
A combined immunotherapy approach that incorporates HSCT,
adoptive transfer of T lymphocytes, and administration of a cell-
based vaccine was unable to eliminate established 5T33 myeloma.
We hypothesized that failure of this immunotherapy to be effective
was due to immune suppression mediated by the B7-H1/PD-1 path-
way. To address this hypothesis, we administered a B7-H1 blocking
antibody to myeloma-bearing mice during the vaccine phase
